New Microbiologica最新文献_第10页

Monkeypox virus transmission in tattoo parlor. 猴痘病毒在纹身店传播。

IF 1.5 4区医学

New Microbiologica Pub Date : 2023-09-01

Carlo Tascini, Francesco Sbrana, Simone Giuliano, Monica Geminiani, Alberto Pagotto

引用次数: 0

Inhibition of S. aureus biofilm formation by linezolid alleviates sepsis-induced lung injury caused by S. aureus infection through direct inhibition of icaA activity. 利奈唑胺对金黄色葡萄球菌生物膜形成的抑制通过直接抑制icaA活性减轻由金黄色葡萄菌感染引起的败血症诱导的肺损伤。

IF 1.8 4区医学

New Microbiologica Pub Date : 2023-09-01

Huan Kuang, Hongxia Bi, Xiaoran Li, Xiaojv Lv, Yanbin Liu

{"title":"Inhibition of S. aureus biofilm formation by linezolid alleviates sepsis-induced lung injury caused by S. aureus infection through direct inhibition of icaA activity.","authors":"Huan Kuang, Hongxia Bi, Xiaoran Li, Xiaojv Lv, Yanbin Liu","doi":"","DOIUrl":"","url":null,"abstract":"Antibiotic-resistant S. aureus infections can be life-threatening. Linezolid is known to hinder S. aureus biofilm formation, but the underlying molecular mechanism remains unclear. Molecular docking revealed that linezolid can bind to icaA, and this was confirmed by thermal drift assays. Linezolid demonstrated a dose-dependent inhibition of icaA enzyme activity. Mutating Trp267, a key residue identified through molecular docking, significantly decreased linezolid binding and inhibitory effects on mutant icaA activity. However, the mutant icaA Trp267Ala showed only slight activity reduction compared to icaA. Linezolid had minimal impact on icaB's thermal stability and activity. The 50S ribosomal L3ΔSer145 mutant S. aureus exhibited similar growth and biofilm formation to the wild-type strain. Linezolid effectively suppressed the growth and biofilm formation of wildtype S. aureus. Although linezolid lost its ability to inhibit the growth of the mutant strain, it still effectively hindered its biofilm formation. Linezolid exhibited weaker attenuation of sepsis-induced lung injury caused by 50S ribosomal L3ΔSer145 mutant S. aureus compared to wild-type S. aureus. These findings indicate that linezolid hampers S. aureus biofilm formation by directly inhibiting icaA activity, independently of its impact on bacterial growth.","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"46 3","pages":"285-295"},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41163863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Barriers to HCV micro-elimination in a cohort of people living with HIV (PLWH). HIV感染者（PLWH）队列中HCV微消除的障碍。

IF 1.8 4区医学

New Microbiologica Pub Date : 2023-09-01

Claudia Bartalucci, Lucia Taramasso, Laura Ambra Nicolini, Laura Magnasco, Laura Labate, Antonio Vena, Sara Mora, Mauro Giacomini, Matteo Bassetti, Antonio Di Biagio

{"title":"Barriers to HCV micro-elimination in a cohort of people living with HIV (PLWH).","authors":"Claudia Bartalucci, Lucia Taramasso, Laura Ambra Nicolini, Laura Magnasco, Laura Labate, Antonio Vena, Sara Mora, Mauro Giacomini, Matteo Bassetti, Antonio Di Biagio","doi":"","DOIUrl":"","url":null,"abstract":"To achieve the World Health Organization goal of hepatitis C virus (HCV) eradication, barriers to treatment should be investigated and overcome. The aim of this study was to identify those barriers and describe the strategies adopted to achieve HCV micro-elimination in a cohort of coinfected people living with HIV (PLWH-HCV). Adult PLWH-HCV followed at our hospital with detectable serum HCV-RNA in 2018 were enrolled. After a three-year follow-up, barriers to HCV treatment were investigated and strategies to overcome them were described. Of 492 PLWH-HCV seen in 2018, 29 (5.9%) had detectable serum HCV-RNA. Eight out of 29 (27.6%) were excluded because they were already under treatment, while 2 others were excluded because they moved to other outpatient clinics. Among the remaining 19 study participants, the most common barriers to treatment were poor adherence to therapies and follow-up visits (n=9, 47%), recent HCV diagnosis awaiting proper staging (n=3, 16%) and treatment hesitancy (n=2, 10%). During the following three years, direct-acting antivirals (DAAs) treatment was completed in 11/19 (58%) cases, with achievement of sustained virological response in 100% of cases. For the remaining cases, 2/19 (10.5%) were lost to follow-up, 2/19 (10.5%) died before treatment initiation and 4/19 (21.0%) are still awaiting treatment. Despite 3 years of effort, HCV micro-elimination has not been achieved at our center. We observed that poor adherence and treatment hesitancy were the main barriers to treatment. Strategies addressing these issues need to be implemented.","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"46 3","pages":"246-251"},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41106913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determination of hepatitis C virus viremia and genotype distribution in Turkish citizens and immigrants from 2018 to 2022. 2018年至2022年土耳其公民和移民丙型肝炎病毒血症和基因型分布的测定。

IF 1.8 4区医学

New Microbiologica Pub Date : 2023-09-01

Murat Yaman, Salih Hazar, Ayfer Bakir

{"title":"Determination of hepatitis C virus viremia and genotype distribution in Turkish citizens and immigrants from 2018 to 2022.","authors":"Murat Yaman, Salih Hazar, Ayfer Bakir","doi":"","DOIUrl":"","url":null,"abstract":"Hepatitis C virus (HCV) infection is an important public health problem with potential risk for Turkey. In order to contribute to the epidemiological data, we aimed to investigate the changes in seroprevalence, viremia rates, and genotypes in the last five years in HCV patients in the southern region of Turkey, which has received heavy migration in recent years, according to demographic criteria. In our study, we analyzed the results retrospectively with demographic data. Conducted at a single center, the study involved 259,875 anti-HCV antibody tests administered between January 2018 and July 2022. The study revealed a prevalence of 0.5% for HCV antibody positivity and a viremia prevalence of 0.1%. Among Turkish nationals, the most common genotypes were GT1 (65.1%), while foreign nationals, mainly of Syrian and Ukrainian origin, showed GT4 (52.3%) as the predominant genotype (p<0.001 for both). Although GT2 (7.4% vs. 4.5%) and GT3 (23.3% vs. 13.6%) were relatively higher in Turkish nationals compared to foreign nationals, the difference was not statistically significant (p=0.750 and p=0.154, respectively). This highlights the importance of continuous monitoring and public health efforts to address the potential impact of these demographic shifts on HCV epidemiology in the region.","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"46 3","pages":"252-257"},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41158010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular epidemiology typing of blaOXA-48 and blaNDM-1 producing Klebsiella pneumoniae causing nosocomial infection. 引起医院感染的blaOXA-48和blaNDM-1产生的肺炎克雷伯菌的分子流行病学分型。

IF 1.8 4区医学

New Microbiologica Pub Date : 2023-09-01

Pegah Shakib, Rashid Ramazanzadeh

引用次数: 0

Seroprevalence of herpes simplex virus type 1 and type 2 - data from a hospital-based study in Varna, northeastern Bulgaria, 2019-2021. 2019-2021年保加利亚东北部瓦尔纳一项医院研究的单纯疱疹病毒1型和2型的血清流行率数据。

IF 1.8 4区医学

New Microbiologica Pub Date : 2023-09-01

Gabriela Tsankova, Tatina Todorova, Neli Ermenlieva, Gergana Nedelcheva, Zhivka Stoykova, Tsvetelina Kostadinova

引用次数: 0

Optimizing Antiretroviral Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in virologically suppressed PLWH. Bitegravir/恩曲他滨/替诺福韦-阿拉芬酰胺在病毒抑制的PLWH中优化抗逆转录病毒治疗。

IF 1.8 4区医学

New Microbiologica Pub Date : 2023-09-01

Massimo Andreoni

{"title":"Optimizing Antiretroviral Therapy with Bictegravir/Emtricitabine/Tenofovir Alafenamide in virologically suppressed PLWH.","authors":"Massimo Andreoni","doi":"","DOIUrl":"","url":null,"abstract":"The pillar of treatment success, defined as viral suppression and immune restoration, should be integrated into a modern vision of therapeutic success with pharmacological attributes of ART, such as potency, forgiveness, and genetic barrier of single drugs and regimens, as well as their longterm tolerability and safety. Moreover, the longterm success of lifelong treatment cannot be separated from the opinions and preferences of PLWH. Regimen Optimization in the setting of HIV suppression may reduce pill burden, and/or dosing frequency, enhance tolerability and/or decrease toxicity, prevent or mitigate DDIs, eliminate food/fluid requirements, relieve pill fatigue, decrease stigma or concerns associated with taking oral med, allow pregnancy, reduce costs (DHHS 2023). Regimen Optimization should be tailored by a person-centered perspective, based on the individual therapeutic history, past toxicities and comorbidities. The treatment strategy should be based on the perceived tolerability and quality of life, considering the preferences of people on treatment along with the virological and pharmacological factors. The health care system should facilitate universal and rapid access to personalized, robust, and effective therapies. The BIC/FTC/TAF association ensures all these characteristics and therefore represents a valid strategy for optimizing treatment in PLWH virologically suppressed.","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"46 3","pages":"231-235"},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41156874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In Silico Evaluation of SARS-CoV-2 K417N, L452R, and E484K Detection Assays Against Omicron Variants. SARS-CoV-2 K417N、L452R和E484K检测组克隆变异的计算机评价

IF 1.8 4区医学

New Microbiologica Pub Date : 2023-05-01

Murat Sayan, Ayse Arikan, Murat Isbilen

引用次数: 0

No need to modify treatment within the first month after rapid start of a tailored antiretroviral therapy: the TWODAY Study. 在快速开始定制抗逆转录病毒治疗后的第一个月内无需修改治疗:TWODAY研究。

IF 1.8 4区医学

New Microbiologica Pub Date : 2023-05-01

Nicola Gianotti, Laura Galli, Michela Sampaolo, Riccardo Lolatto, Elisabetta Carini, Gaetana Annicchiarico, Alessandro Baglivi, Liviana Della Torre, Adriano Lazzarin, Antonella Castagna

{"title":"No need to modify treatment within the first month after rapid start of a tailored antiretroviral therapy: the TWODAY Study.","authors":"Nicola Gianotti, Laura Galli, Michela Sampaolo, Riccardo Lolatto, Elisabetta Carini, Gaetana Annicchiarico, Alessandro Baglivi, Liviana Della Torre, Adriano Lazzarin, Antonella Castagna","doi":"","DOIUrl":"","url":null,"abstract":"The aim of the TWODAY Study was to investigate the frequency of early treatment change after rapid start of a tailored ART regimen (a 2-drug regimen - 2DR, when clinically feasible or a 3-drug regimen - 3DR, otherwise). TWODAY was an open-label, prospective, proof-of-concept, single center study. ART-naïve patients started their first-line regimen within a few days from the first laboratory testing with a 2DR of dolutegravir (DTG) and lamivudine (3TC) if CD4+ count >200 cells/mL, HIVRNA <500,000 copies/mL, no transmitted drug resistance to DTG or 3TC and HBsAg undetectable; otherwise, ART was started with a 3DR. The primary endpoint was the proportion of patients who needed to change ART within four week from start, for any reason. Thirty-two patients were enrolled; 19 (59.3%) were deemed eligible for a 2DR. Median time from laboratory testing to ART start was 5 days (5; 5). No regimen modification occurred within one month. In conclusion, no regimen modification was needed within the first month of treatment. Starting a 2DR within a few days after HIV diagnosis was feasible, relying upon complete results of the needed laboratory tests (including resistance testing). A 2DR can be safely proposed provided full laboratory tests are readily available.","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"46 2","pages":"154-160"},"PeriodicalIF":1.8,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9545959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Susceptibility of ceftolozane/tazobactam against multidrug-resistant and carbapenem-resistant Pseudomonas aeruginosa. 头孢唑烷/他唑巴坦对多重耐药和碳青霉烯耐药铜绿假单胞菌的敏感性。

IF 1.8 4区医学

New Microbiologica Pub Date : 2023-05-01

Ayaka Kakehi, Hideharu Hagiya, Koji Iio, Takumi Fujimori, Mami Okura, Hiroshi Minabe, Yukika Yokoyama, Fumio Otsuka, Akihito Higashikage

引用次数: 0